The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door ...

The agency's decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday ... The study included 751 adults with obesity or overweight who also ...

Eli Lilly LLY recently announced its plans to spend $3 ... However, the latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications. On ...

ELI Lilly is spending another US$3 billion to build out ... the most valuable pharmaceutical company in the world. Zepbound, used to treat obesity, and Mounjaro, a diabetes drug, are in extremely high ...